Aytu Bioscience Stock Net Income
| AYTU Stock | USD 1.62 0.02 1.25% |
Aytu BioScience fundamentals help investors to digest information that contributes to Aytu BioScience's financial success or failures. It also enables traders to predict the movement of Aytu Stock. The fundamental analysis module provides a way to measure Aytu BioScience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aytu BioScience stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -15.8 M | -16.6 M | |
| Net Loss | -15.8 M | -16.6 M | |
| Net Loss | -15.3 M | -16.1 M | |
| Net Loss | (2.86) | (619,854) | |
| Net Income Per E B T | 1.13 | 0.87 |
Aytu | Net Income |
Aytu BioScience Company Net Income Analysis
Aytu BioScience's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Aytu BioScience Net Income | (15.84 M) |
Most of Aytu BioScience's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aytu BioScience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aytu Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Aytu BioScience is extremely important. It helps to project a fair market value of Aytu Stock properly, considering its historical fundamentals such as Net Income. Since Aytu BioScience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aytu BioScience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aytu BioScience's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Aytu Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Aytu BioScience reported net income of (15.84 Million). This is 104.64% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 102.77% higher than that of the company.
Aytu Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aytu BioScience's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aytu BioScience could also be used in its relative valuation, which is a method of valuing Aytu BioScience by comparing valuation metrics of similar companies.Aytu BioScience is currently under evaluation in net income category among its peers.
Aytu BioScience Institutional Holders
Institutional Holdings refers to the ownership stake in Aytu BioScience that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aytu BioScience's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aytu BioScience's value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 880 | Jpmorgan Chase & Co | 2024-06-30 | 540 | Ubs Group Ag | 2024-06-30 | 308 | Advisor Group Holdings, Inc. | 2024-06-30 | 300 | Wells Fargo & Co | 2024-06-30 | 124 | Bank Of America Corp | 2024-06-30 | 92.0 | Atlantic Trust Group, Llc | 2024-06-30 | 83.0 | Group One Trading, Lp | 2024-06-30 | 37.0 | Goss Wealth Management Llc | 2024-06-30 | 21.0 | Nantahala Capital Management, Llc | 2024-09-30 | 1.1 M | Stonepine Capital Management Llc | 2024-06-30 | 472.5 K |
Aytu Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.0106 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 6.29 M | ||||
| Shares Outstanding | 6.15 M | ||||
| Shares Owned By Insiders | 2.43 % | ||||
| Shares Owned By Institutions | 34.04 % | ||||
| Number Of Shares Shorted | 192.76 K | ||||
| Price To Earning | (0.77) X | ||||
| Price To Book | 0.33 X | ||||
| Price To Sales | 0.12 X | ||||
| Revenue | 81 M | ||||
| Gross Profit | 66.63 M | ||||
| EBITDA | (1.01 M) | ||||
| Net Income | (15.84 M) | ||||
| Cash And Equivalents | 23.81 M | ||||
| Cash Per Share | 0.38 X | ||||
| Total Debt | 15.13 M | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 1.02 X | ||||
| Book Value Per Share | 4.64 X | ||||
| Cash Flow From Operations | (1.39 M) | ||||
| Short Ratio | 10.45 X | ||||
| Earnings Per Share | (1.70) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 102 | ||||
| Beta | -1.4 | ||||
| Market Capitalization | 9.84 M | ||||
| Total Asset | 118.09 M | ||||
| Retained Earnings | (319.97 M) | ||||
| Working Capital | (337 K) | ||||
| Current Asset | 6.36 M | ||||
| Current Liabilities | 8.73 M | ||||
| Net Asset | 118.09 M |
About Aytu BioScience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aytu BioScience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aytu BioScience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aytu BioScience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.